ABSTRACT
Objective To determine bimatoprost， tafluprost ethyl amide， latanoprost， travoprost and tafluprost in eyelash enhancing cosmetics by establishing a LC-MS/MS method. Methods The samples were extracted with a 50% acetonitrile water solution. A salt mixture（4 g NaCl， 1 g MgSO4） was added to the solution to induce phase separation. After centrifugation and filtration， the analysis of five prostaglandin analogs was performed with an Agilent Poroshell 120 PFP-C18 （2.7 μm， 2.1 mm×100 mm） column， using 0.02% formic acid containing 5 mmol·L-1 Acetic acid amine and acetonitrile by gradient elution at a flow rate of 0.5 mL·min-1. The analytes were detected with electrospray ionization source in positive ion mode （ESI+） and multiple reaction monitoring （MRM）， and quantified by external standard curve. Results The results showed that it had a good linearity in the range of locatable ambit of concentration with correlation coefficients （r） larger than 0.999. The detection limit of five prostaglandin analogs （LOD） was 0.000 2‒1.5 μg·g-1. The spiked recoveries were 93.2% to 103.5% with a relative standard deviation （RSD） of 1.2% to 3.4%. Conclusion The method is simple， rapid and highly sensitive. It is suitable for the determination of five prostaglandin analogs in eyelash enhancing cosmetics.
ABSTRACT
Medication treatment is the most common measure for lowering intraocular pressure in glaucoma, and prostaglandin analogues have been unanimously recommended as the first choice for the treatment of glaucoma in multiple guidelines or consensus.Real-world studies (RWS) are observational studies in which diverse data are obtained in clinical environment, community or home settings to evaluate the real impact of some treatment on patients’ health.RWS have shown that tafluprost has a good effect on lowering intraocular pressure in patients with primary open angle glaucoma, ocular hypertension, normal tension glaucoma and other types of glaucoma, and it has mild ocular adverse effects in monotherapy for treatment-naive patients, alternative therapy and combination therapy.However, there are limiting factors for RWS such as the absence of the control group, and further studies are needed to evaluate the drug efficacy.In this article, the RWS of patients with different types of glaucoma and high intraocular pressure treated by tafluprost and the efficacy of tafluprost under different treatment modes as well as the safety of tafluprost and medication compliance in RWS were reviewed, so as to provide certain guidance for the practical clinical application of tafluprost.
ABSTRACT
PURPOSE: This study evaluated the effect of a fixed combination of 0.0015% tafluprost-0.5% timolol (Tapcom®, Santen, Osaka, Japan) in glaucoma patients. METHODS: This study included 23 patients who were diagnosed with normal tension glaucoma and treated with a fixed combination of 0.0015% tafluprost-0.5% timolol as the first therapy. Diurnal intraocular pressure (IOP) was measured every 2 and 0.5 hours between 9:00 am and 4:30 pm. The IOP change with respect to body position (positional IOP) was measured at baseline and at 6 months after eye-drop instillations. IOP fluctuation was defined as the standard deviation of IOP measurements. Throughout the study, all side effects were recorded and monitored by the investigators. RESULTS: The mean reduction in IOP in the 0.0015% tafluprost-0.5% timolol fixed combination-treated eyes was −3.37 ± 2.39 mmHg (−19.70 ± 13.97%) for the right eye and −3.22 ± 2.27 mmHg (-18.81 ± 13.28%) for the left eye (paired t-test, p < 0.001). The mean positional IOP measured at 4 pm at 6 months after 0.0015% tafluprost-0.5% timolol fixed combination instillation showed statistically significant reduction from the mean positional IOP at baseline. There was a significant difference in the number of patients with ≤3 mmHg IOP variation over four time points between baseline and at 6 months in the 0.0015% tafluprost-0.5% timolol fixed combination-treated eyes (McNemar test, p < 0.001). There was no serious adverse event causing ocular damage. CONCLUSIONS: Use of 0.0015% tafluprost-0.5% timolol fixed combination was effective and well tolerated in reducing IOP and in maintaining its effectiveness in glaucoma patients.
Subject(s)
Humans , Glaucoma , Intraocular Pressure , Low Tension Glaucoma , Research Personnel , TimololABSTRACT
Background: This prospective, open, randomized, parallel-group, comparative study is to evaluate the efficacy and side-effect profile of travoprost (TRAV) 0.004% compared with tafluprost (TAF) 0.0015% in patients with primary open-angle glaucoma (POAG) over 12 weeks. A total of 80 patients of POAG selected and were randomized to either TRAV or TAF monotherapy administered once daily in the evening for 12 weeks. Methods: The study was conducted on 80 cases of POAG, in which patients were randomized to either TRAV or TAF monotherapy administered as 1 drop daily in the evening for 12 weeks. Intraocular pressure (IOP) was measured (8 am, 12 noon and 4 pm) at each visit, slit-lamp bio-microscopy was done and side effects noted. Results: The mean IOP reduction in TRAV group decreased from 27.58±2.30 to 19.03±2.326 thus resulting in fall of 8.55 (31.0%) and in TAF group it decreased from 27.38±2.676 to 20.58±2.827 resulting in fall of 6.8 mm Hg (24.8%) was significant (p<0.05). In both treatment groups, the most frequently reported adverse event at 12 weeks was red eye, noted in, 9 (22.5%) and 7 (17.5%) cases of TRAV and TAF groups respectively, though the difference was not statistically significant. Conclusion: TRAV 0.004% monotherapy produced lower diurnal IOP than TAF 0.0015% in patients with POAG and exhibited a similar safety profile.
ABSTRACT
PURPOSE: To report a single case of herpes simplex keratitis after application of 0.015% tafluprost eye drops. CASE SUMMARY: A 68-year-old male presented with left eye discomfort, epiphora, decreased visual acuity and hyperemia. The patient was diagnosed with glaucoma 6 weeks prior and started on 0.015% tafluprost eye drops in left eye and 0.15% brimonidine in both eyes. On slit lamp examination dendritic epithelial defect was observed and the patient was diagnosed with herpes simplex keratitis. The 0.015% tafluprost treatment was discontinued and 0.15% brimonidine was applied in both eyes twice a day. The herpetic keratitis in his left eye resolved completely in 2 weeks with acyclovir ointment and oral antiviral agent. No further recurrence was observed in the following 3 months.